Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
Recruiting · NCT06943495 · Registry updated 2025-09-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Recruiting | Phase 1 | 2025-09-09 | NCT06943495 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Canadian Institutes of Health Research (CIHR) | 339 |
| CHU de Quebec-Universite Laval | 54 |
| Jean-Mathieu Beauregard | 1 |
| Novartis | 114 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| CHU de Québec-Université Laval | Québec | Canada | 1 |